trending Market Intelligence /marketintelligence/en/news-insights/trending/w4EZ1tsG2rKzIx7PpAO5Wg2 content esgSubNav
In This List

Generex Biotechnology acquires additional 38% of wound-care company Olaregen

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Generex Biotechnology acquires additional 38% of wound-care company Olaregen

Generex Biotechnology Corp. purchased an additional 38% stake in Olaregen Therapeutix Inc., bringing it close to full ownership after the share exchange at $2.50 apiece for Generex stock was applied.

The acquisition aligns with the market launch of Olaregen's wound-conforming gel Excellagen. The treatment has received U.S. Food and Drug Administration clearance to treat wounds such as diabetic ulcers and surgical wounds.

"Today's buyout of the Olaregen shareholders was unexpected and we are very happy that those shareholders believe enough in the Generex strategy that they exchanged their private shares for Generex public shares, further demonstrating to us and our shareholders the value we are creating," Generex President and CEO Joseph Moscato said in a statement.

Miramar, Fla-based Generex develops cancer therapies, medical devices and diagnostics. It acquired 51% of Olaregen in January and also bought a stake in another regenerative medicine company, Regentys Corp., earlier this year.